Baxter International Faces Class Action as Investors Seek Lead Role

Investors in Baxter International, Inc. have the opportunity to lead a class action lawsuit against the company and certain executives for alleged violations of the Securities Exchange Act of 1934. The legal action, initiated by the Electrical Workers Pension Fund, Local 103, pertains to common stock purchases made between February 23, 2022, and July 30, 2025. Individuals wishing to serve as lead plaintiffs must submit their information by December 15, 2025.

The lawsuit, filed in the Northern District of Illinois under case number 25-cv-12672, accuses Baxter and its executives of making false statements and failing to disclose critical information about the company’s Novum IQ Large Volume Pump (Novum LVP). Significant allegations include claims that the device suffered from systemic defects that led to malfunctions, posing serious risks to patient safety.

According to the complaint, Baxter was aware of multiple incidents involving device failures resulting in severe injury or death. The lawsuit asserts that the company’s attempts to mitigate these issues through customer alerts were insufficient, as design flaws persisted, causing ongoing harm.

On July 31, 2025, Baxter announced a “voluntary and temporary pause” on shipments and installations of the Novum LVP, citing an inability to provide a timeline for resuming sales. Following this announcement, the company’s stock price plummeted by more than 22%, reflecting investor concerns over the future of the product.

The Private Securities Litigation Reform Act of 1995 allows investors who purchased Baxter’s common stock during the specified Class Period to seek lead plaintiff status. This role typically goes to the investor with the most significant financial loss who also represents the interests of the entire class. Importantly, being a lead plaintiff does not affect an investor’s eligibility to receive any potential recovery from the lawsuit.

Robbins Geller Rudman & Dowd LLP, the firm representing the plaintiffs, is recognized as one of the leading firms in securities fraud and shareholder litigation. The firm has a strong track record, having secured over $2.5 billion for investors in 2024 alone, according to ISS Securities Class Action Services.

Interested investors can learn more about joining the class action or providing information by contacting Robbins Geller at 800-449-4900 or via email at [email protected]. For further details about the lawsuit, visit the firm’s website.

This class action represents a significant moment for Baxter International, as it navigates legal challenges and seeks to address serious allegations that could impact its reputation and financial stability. The outcome will likely have broader implications for investors and the healthcare sector as a whole.